Core Viewpoint - Ganlee Pharmaceutical Co., Ltd. reported significant growth in revenue and profit for the first half of 2025, indicating strong operational performance despite a slight decrease in total assets compared to the previous year [1]. Group 1: Financial Performance - Total assets at the end of the reporting period were approximately ¥11.88 billion, a decrease of 1.37% from the previous year [1]. - Revenue for the reporting period reached ¥2.07 billion, representing a 57.18% increase compared to the same period last year [1]. - Total profit amounted to approximately ¥691 million, showing a substantial increase of 102.73% year-on-year [1]. - Net profit attributable to shareholders was approximately ¥488 million, which is a remarkable increase of 284.47% compared to the same period last year [1]. Group 2: Shareholder Information - The total number of shareholders at the end of the reporting period was 77,299 [2]. - The largest shareholder, Gan Zhongru, holds 34.21% of the shares, amounting to approximately 205.64 million shares [2]. - Other significant shareholders include Beijing Xutong Hongda Technology Co., Ltd. with 5.90% and Hong Kong Central Clearing Limited with 1.25% [2].

Core Viewpoint - Gan & Lee Pharmaceuticals has achieved significant growth in the first half of 2025, with a focus on innovation and research in diabetes treatment, particularly in insulin products and GLP-1 receptor agonists [2][3][21]. Financial Performance - The company reported a revenue of 2.067 billion yuan, a year-on-year increase of 57.18%, and a net profit of 604 million yuan, up 101.96% compared to the previous year [2][8]. - Domestic business revenue reached 1.845 billion yuan, growing by 55.28%, while international business revenue was 222 million yuan, increasing by 75.08% [2][8][9]. - The company distributed cash dividends totaling 598 million yuan, representing 97.21% of the net profit attributable to shareholders for 2024 [2]. Research and Development - R&D investment for the first half of 2025 was 552 million yuan, accounting for 26.70% of total revenue [2][3][21]. - The company is advancing its third-generation insulin technology and is in the global Phase III clinical stage for its GZR4 insulin product and GLP-1RA drug, Bo Fang Ge Lu Tai [2][3][21]. Market Expansion - Gan & Lee has expanded its international market presence, receiving product approvals in countries like Malaysia, Pakistan, and Argentina [4][22]. - The company aims to provide more accessible treatment options globally, leveraging its innovative products and competitive pricing [4][22]. Industry Context - The Chinese pharmaceutical industry is experiencing a shift towards innovation-driven development, with government policies supporting the rapid approval and clinical application of new drugs [13][19]. - The insulin procurement policy in China is enhancing the competitiveness of domestic companies, allowing them to capture a larger market share [14][20]. Strategic Focus - The company is committed to integrating scientific excellence into daily operations and quantifying patient benefits through reliable clinical data [4][21]. - Gan & Lee is actively pursuing global partnerships and expanding its capabilities in compliance, production, and commercialization to strengthen its international presence [22].

二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： （一）审议通过了《关于公司 2025 年半年度报告及摘要的议案》 公司 2025 年半年度报告的编制及审议程序符合相关法律、法规、规范性文 件及《公司章程》的规定，公司严格按照上市公司财务制度规范运作；报告真实、 全面地反映了公司本报告期的财务状况和经营成果；报告所披露的信息真实、准 确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏，在监事会做出本决 议前，未发现参与报告编制与审议人员存在违反保密规定的行为。 证券代码：603087 证券简称：甘李药业 公告编号：2025-059 甘李药业股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 甘李药业股份有限公司（"公司"）第五届监事会第三次会议于 2025 年 7 月 议室以现场会议的形式召开。本次会议由监事会主席张立主持。应出席监事 3 名，实际出席监事 3 名。本次会议的召开符合《公司法》和《公司章程》的有关 规定，会议决议合法有效。 具体内容详见公司于同日在上海证券交易所 ...

Core Viewpoint - The leading companies in the insulin market, namely Ganli Pharmaceutical and Tonghua Dongbao, have shown signs of recovery in their financial performance, indicating a positive trend following two rounds of centralized procurement [1][2]. Group 1: Financial Performance - Tonghua Dongbao expects a net profit of approximately 217 million yuan for the first half of 2025, marking a turnaround from losses in the previous year [1]. - Ganli Pharmaceutical reported a revenue of 2.067 billion yuan and a net profit of 604 million yuan for the first half of 2025, representing year-on-year increases of 57.18% and 101.96%, respectively [3]. Group 2: Revenue Growth Drivers - Tonghua Dongbao attributes its turnaround to significant sales growth of insulin analog products and successful international expansion, leading to a notable increase in export revenue [2]. - Ganli Pharmaceutical's domestic revenue reached 1.845 billion yuan, a year-on-year increase of 55.28%, with its formulation sales growing by 57.09% [2]. Group 3: International Expansion - Ganli Pharmaceutical has received approvals for its products in countries such as Malaysia, Pakistan, and Argentina, and has successfully introduced insulin production technology in Brazil [4]. - Tonghua Dongbao has also expanded its international presence, with its insulin products approved for sale in Uzbekistan and Nicaragua [4]. Group 4: R&D Focus - The companies are shifting their focus towards developing new products, including fourth-generation insulin and GLP-1 class hypoglycemic drugs, as traditional insulin products face profit pressures from centralized procurement [5]. - Ganli Pharmaceutical is advancing several clinical projects, including GZR4 and GZR101, which are in different phases of clinical trials, and its GLP-1RA dual-week formulation, Bofanglure, is in phase III clinical research [5][6].

Mergers and Acquisitions - Tengjing Technology has decided to terminate the acquisition of 100% shares of Xunke Communication due to changes in market conditions and difficulties in reaching an agreement on the transaction plan [1] Earnings Disclosure - Ganli Pharmaceutical reported a revenue of 2.067 billion yuan for the first half of 2025, representing a year-on-year increase of 57.18%, and a net profit of 604 million yuan, up 101.96% year-on-year [2] - Shangwei New Materials announced a revenue of 784 million yuan for the first half of 2025, a year-on-year increase of 12.50%, but a net profit of 29.90 million yuan, down 32.91% year-on-year [3] - SMIC reported a sales revenue of 2.209 billion USD for the second quarter of 2025, a quarter-on-quarter decrease of 1.7%, with a gross margin of 20.4%, down 2.1 percentage points quarter-on-quarter [4] Shareholding Changes - Babai Co. announced that its major shareholder, Guangzhou Yunmei Industrial Investment Partnership, plans to reduce its holdings by no more than 2% of the company's shares, equivalent to 223.08 million shares [5] - Xianheng International disclosed that its major shareholder, Goldman Sachs Asia, intends to reduce its holdings by no more than 3%, which amounts to 12.30 million shares [6] - Linuo Pharmaceutical Packaging announced that its shareholders plan to reduce their holdings by no more than 3%, totaling 697.87 million shares [7] Risk Events - Fangsheng Pharmaceutical announced that its actual controller, Zhang Qinghua, has been placed under residential surveillance starting from August 6, 2025 [8]

Core Viewpoint - 甘李药业 reported strong financial performance for the first half of 2025, with significant growth in both revenue and net profit, driven by domestic and international market expansion, innovative product development, and a robust dividend policy [1][2][5]. Financial Performance - The company achieved a revenue of 2.067 billion yuan, representing a year-on-year increase of 57.18% [1]. - Net profit attributable to shareholders reached 604 million yuan, marking a year-on-year growth of 101.96% [1]. Domestic Market Performance - Domestic sales reached 1.845 billion yuan, up 55.28% year-on-year, largely due to the renewal of insulin national procurement agreements, which increased procurement volume by 32.6% [2]. - The overall sales volume of domestic formulations grew by 33.55% year-on-year [2]. - The company's market share in third-generation insulin rose to second in the industry, following Novo Nordisk [2]. International Market Expansion - International sales amounted to 219 million yuan, reflecting a year-on-year increase of 74.68% [2]. - The company is actively pursuing globalization through initiatives aligned with the Belt and Road Initiative, establishing partnerships in over 20 countries [2]. Research and Development - R&D investment totaled 552 million yuan, accounting for 26.70% of revenue, focusing on fourth-generation insulin and GLP-1 drugs [3]. - The fourth-generation insulin GZR4 has entered Phase III clinical trials domestically and has been approved for Phase I trials in Europe and the U.S. [3]. - The GLP-1 RA drug, Bo Fang Ge Lu Tai, is in Phase III trials in China and Phase II in the U.S., showing promising results in head-to-head trials [3]. International Milestones - The company achieved significant milestones in international markets, including the registration of multiple insulin products in Malaysia and the approval of its insulin product in Pakistan [4]. - A collaboration with Brazil's Ministry of Health marks the company's entry into Brazil's public health system, enhancing its international strategy [4]. Dividend Policy and Market Confidence - The company implemented a cash dividend of 1 yuan per share, totaling 598 million yuan, which represents 97.21% of the net profit attributable to shareholders for 2024 [5]. - Since its listing in 2020, the company has distributed cash dividends totaling 1.612 billion yuan, with an average cash dividend rate of 592.80% over the past three years [5]. Long-term Outlook - With improved operations, successful innovation, and international expansion, the sustainability of profit distribution is expected to enhance, along with the company's long-term investment value and competitiveness in the global metabolic disease sector [6].

Mergers and Acquisitions - Tengjing Technology has decided to terminate the acquisition of 100% shares of Xunke Communication due to changes in market conditions and difficulties in reaching an agreement on the transaction plan [1] Performance Disclosure - Ganli Pharmaceutical reported a revenue of 2.067 billion yuan for the first half of 2025, representing a year-on-year increase of 57.18%, and a net profit of 604 million yuan, up 101.96% year-on-year [2] - Shunwei New Materials announced a revenue of 784 million yuan for the first half of 2025, a year-on-year increase of 12.50%, but a net profit of 29.90 million yuan, down 32.91% year-on-year [3] - SMIC reported a sales revenue of 2.209 billion USD for the second quarter of 2025, a quarter-on-quarter decrease of 1.7%, with a gross margin of 20.4%, down 2.1 percentage points quarter-on-quarter [4] Shareholding Changes - Babai Co. announced that its major shareholder, Guangzhou Yunmei Industrial Investment Partnership, plans to reduce its holdings by no more than 223.08 million shares, accounting for 2% of the total share capital [5] - Xianheng International disclosed that its major shareholder, Goldman Sachs Asia, intends to reduce its holdings by no more than 12.30 million shares, representing no more than 3% of the total shares [6] - Lino Pharmaceutical Packaging announced that its shareholders plan to reduce their holdings by no more than 697.87 million shares, accounting for 3% of the total share capital [7] Risk Events - Fangsheng Pharmaceutical announced that its actual controller, Zhang Qinghua, has been placed under residential surveillance starting from August 6, 2025 [8]

Core Viewpoint - Ganli Pharmaceutical (603087.SH) reported significant growth in its 2025 semi-annual results, with revenue reaching 2.067 billion yuan, a year-on-year increase of 57.18%, and net profit attributable to shareholders at 604 million yuan, up 101.96% [1] Group 1: Financial Performance - Revenue for the reporting period was 2.067 billion yuan, reflecting a 57.18% year-on-year growth [1] - Net profit attributable to shareholders was 604 million yuan, representing a 101.96% increase [1] - Deducted non-recurring net profit reached 488 million yuan, showing a substantial growth of 284.47% [1] - Basic earnings per share stood at 1.02 yuan [1] Group 2: Domestic Sales - Domestic sales revenue amounted to 1.845 billion yuan, an increase of 655 million yuan, or 55.28% year-on-year [1] - Domestic formulation sales revenue was 1.802 billion yuan, up 57.09% compared to the previous year [1] - The company successfully expanded its market share through two rounds of insulin centralized procurement, with the first-year procurement agreement volume increasing by 32.6% in the 2024 follow-up procurement [1] - The impact of sales volume growth on revenue was 385 million yuan, while price growth contributed 270 million yuan [1] - Overall domestic formulation sales volume increased by 33.55%, with all formulation products showing positive growth [1] Group 3: International Sales - International revenue reached 222 million yuan, an increase of 95 million yuan, or 75.08% year-on-year [2] - The growth in international revenue was driven by the company's ongoing global strategy [2] - The company deepened stable partnerships with key market leaders, leveraging customer trust to promote a diverse product portfolio and explore new growth opportunities [2]

甘李药业股份有限公司 2025 年半年度募集资金存放、管理与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会发布的《上市公司募集资金监管规则》等相关 规定，现将甘李药业股份有限公司（以下简称"公司"）2025 年半年度募集资 金存放、管理与使用情况专项报告披露如下： 一、 募集资金基本情况 证券代码：603087 证券简称：甘李药业 公告编号：2025-060 经中国证券监督管理委员会以"证监许可[2020]1075 号"文《关于核准甘 李药业股份有限公司首次公开发行股票的批复》核准，公司向社会公开发行人民 币普通股 40,200,000 股（A 股），每股面值人民币 1 元，发行价格为人民币 63.32 元/股，募集资金总额为人民币 2,545,464,000.00 元。扣减发行上市费用人民币 104,329,536.23 元（由于本公司对外销售自产的胰岛素产品按 3%的简易征收率 缴纳增值税，不予抵扣进项税，上述发行费用包含增值税金）后，本公司此次发 行 A 股募集资金净 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-059 甘李药业股份有限公司 第五届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 甘李药业股份有限公司（"公司"）第五届监事会第三次会议于 2025 年 7 月 26 日以电子邮件方式发出会议通知和会议材料，2025 年 8 月 6 日在公司五层会 议室以现场会议的形式召开。本次会议由监事会主席张立主持。应出席监事 3 名，实际出席监事 3 名。本次会议的召开符合《公司法》和《公司章程》的有关 规定，会议决议合法有效。 二、监事会会议审议情况 （一）审议通过了《关于公司 2025 年半年度报告及摘要的议案》 公司 2025 年半年度报告的编制及审议程序符合相关法律、法规、规范性文 件及《公司章程》的规定，公司严格按照上市公司财务制度规范运作；报告真实、 全面地反映了公司本报告期的财务状况和经营成果；报告所披露的信息真实、准 确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏，在监事会做出本决 议前，未发现参与报 ...